Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment

Brun, Bernard; Benchalal, M.; Lebas, Christelle; Piedbois, Pascal; Lin, Ma Bin; Lebourgeois, Jean-Paul

doi:10.1002/(sici)1097-0142(19970601)79:11<2137::aid-cncr11>3.0.co;2-x

Cited by 16 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Liver metastasis is found in about 15% of patients with metastatic breast cancer, 2 but only 4%-5% of these patients present with isolated liver metastasis. 2,3 Thus, the dissemination of disease to other sites usually contraindicates liver resection.…”

Section: Introductionmentioning

confidence: 99%

Liver resection for breast cancer metastasis: Does it improve survival?

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Liver resection for breast cancer metastasis: Does it improve survival?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Alternatively, recurrence of hormone receptor-negative disease may be treated with single-agent, sequential chemotherapy, or combination chemotherapy [1]. If recurrence of hormone receptor-negative disease occurs many years after administration of adjuvant anthracycline-and taxane-containing chemotherapy, re-treatment with drugs within these classes may still remain an appropriate treatment choice [6]. If recurrence occurs within a year of this adjuvant treatment, other chemotherapy classes would generally be preferable.…”

Section: Introductionmentioning

confidence: 99%

Optimizing the treatment of metastatic breast cancer

Gralow

2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

There is currently no standard care for metastatic breast cancer; consequently, individual patient and tumor characteristics are among several factors considered in treatment decisions. Clinical studies continue to clarify the roles of endocrine therapy, chemotherapy, and biologic therapy, and results have been promising. For patients with hormone receptor-positive disease, several endocrine agents are currently available including selective estrogen receptor (ER) modulators (tamoxifen and toremifene), aromatase inhibitors (anastrozole, exemestane, and letrozole), as well as the selective ER down-regulator, fulvestrant. Effective first- and second-line, single-agent chemotherapeutic treatments include the taxanes, anthracyclines, vinorelbine, capecitabine, and gemcitabine. The benefits of sequential, single-agent versus combination chemotherapy are also being evaluated. Although combination chemotherapy generally results in a greater objective response, it is associated with similar survival and usually greater toxicity compared with sequential, single-agent chemotherapy. Research involving biologic therapy continues to provide encouraging results for patients with metastatic breast cancer. Chemotherapy plus trastuzumab has been shown to result in greater overall survival versus chemotherapy alone in human epidermal growth factor 2 (HER-2)-positive patients. Trastuzumab has been associated with cardiotoxicity when administered with conventional anthracyclines. Newer formulations of anthracyclines have been developed (e.g., liposomal anthracyclines) to decrease the incidence of cardiotoxicity, and these provide additional treatment options for patients with metastatic breast cancer. The potential effect of all of these endocrine, chemotherapeutic, and biologic treatments on quality of life is an important consideration. Additionally, integrating patient concerns into treatment decisions and collaborating with cross-disciplinary healthcare providers can help to manage the disease more effectively.

show abstract

“…Interestingly, 6 studies found that patients with a response and/or longer TTP or PFS of previous chemotherapy also had longer TTP or PFS on next-line chemotherapy. [84][85][86][87][88][89][90] Additionally, the median PFS of 11 months for second-line chemotherapy measured in the study by Brun et al 90 is long compared with the other studies evaluating second-line chemotherapy (Figure 7.2B). This might be explained by the fact that this study only selected patients who had a complete or partial response to first-line chemotherapy, supporting this notion of a possible prognostic role for response to previous-line chemotherapy for the length of next-line PFS.…”

Section: Multiple Chemotherapy Lines In Clinical Practice: Number Of ...mentioning

confidence: 83%

“…A remarkable finding was the significant association between outcomes from previous chemotherapy regimens and outcomes of next-line chemotherapy described in 6 real-world studies. [84][85][86][87][88][89][90] Furthermore, response to previous chemotherapy 88,89,94,111,112 and longer PFS 84,93,113 was described to significantly increase OS in observational trials. The relationship between PFS and OS was also seen within approval studies of chemotherapy and previously described in a systematic review specifically focusing on first-line (mean ratio of median PFS: median OS of 1/3).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy in advanced breast cancer

Claessens

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment

Abstract: Retained chemosensitivity appeared to be an important characteristic in patients responding to second-line chemotherapy.

Cited by 16 publications

References 43 publications

Liver resection for breast cancer metastasis: Does it improve survival?

Liver resection for breast cancer metastasis: Does it improve survival?

Optimizing the treatment of metastatic breast cancer

Chemotherapy in advanced breast cancer

Contact Info

Product

Resources

About